Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at financialmarketpress.com, will continue to monitor these healthtech companies to see if the momentum continues. FinancialMarketPress.com is looking into these tickers DAWN, MTDR, AVY, CMC, MNST, RTX and more..
Recent SRPT Stock Price: $122.69
Summary: Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. It concentrates on the development of exon-skipping drug candidates targeting Duchenne muscular dystrophy (DMD), a rare genetic disorder affecting children. The company received accelerated approval for Exondys 51, Amondys 45 (casimersen) and Vyondys 53 (golodirsen). Exondys 51 is Sarepta's first PMO-based technology to be granted accelerated approval by the FDA. The company is conducting a confirmatory study on the clinical benefits of these drugs for gaining continued approval. The rest of its exon-skipping DMD pipeline includes a PPMO-based, exon 51 skipping candidate, SRP-5051. Sarepta is also developing gene therapies for treating DMD, Limb-girdle muscular dystrophy and central nervous system disorders including Mucopolysaccharidosis type IIIA and Pompe Disease.
Tim Lugo analyst at William Blair reiterates coverage on Sarepta Therapeutics (SRPT) stock in the energy sector with a Buy rating and Lugo has not provided a price target for SRPT stock.
TipRanks.com reports that Sarepta Therapeutics currently has 19 analysts offering 12-month price targets on SRPT and the consensus is a Strong Buy rating with an average stock price target of $167.53. The most recent SRPT stock price we have is $122.69 and we are not making any SRPT forecasts at this time.
In addition, TradingView issued a Sell rating for SRPT over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on SRPT. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on SRPT, please click here >>
Quest Diagnostics, DGX
Recent DGX Stock Price: $131.53
Summary: Quest Diagnostics, Inc. is the provider of commercial laboratory services. Quest provides lab testing services to physicians, hospitals, managed care organizations, employers, government institutions and other clinical laboratories. The company consists of 2 business groups - Diagnostic Information Services and Diagnostic Solutions. The company's focus is on two elements - to accelerate growth and to drive operational excellence. Restore Growth: The company has adopted seven tactical approaches to accelerate growth such as sales and marketing; development of esoteric testing through a disease focus; partnerships with hospitals and successful testing of international IDNs; creation of value from information assets; leadership in companion diagnostics; extension into adjacent markets. Drive Operational excellence: The company plans to focus on four strategic requirements - to enhance end-to-end customer value chain, enterprise information technology architecture, business performance tools and cost excellence.
Erin Wright analyst at Morgan Stanley reiterates coverage on Quest Diagnostics (DGX) stock in the energy sector with a Hold rating and has set DGX's stock price target at $ 158.
TipRanks.com reports that Quest Diagnostics currently has 9 analysts offering 12-month price targets on DGX and the consensus is a Hold rating with an average stock price target of $154.56. The most recent DGX stock price we have is $131.53 and we are not making any DGX forecasts at this time.
In addition, TradingView issued a Strong Sell rating for DGX over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on DGX. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on DGX, please click here >>
Adicet Bio, ACET
Recent ACET Stock Price: $7.43
Summary: Adicet Bio Inc. is a biotechnology company. It engages in discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet Bio Inc., formerly known as RESTORBIO INC, is based in Calif.
Reni Benjamin analyst at JMP Securities reiterates coverage on Adicet Bio (ACET) stock in the energy sector with a Buy rating and has set ACET's stock price target at $ 19.
TipRanks.com reports that Adicet Bio currently has 5 analysts offering 12-month price targets on ACET and the consensus is a Strong Buy rating with an average stock price target of $26.40. The most recent ACET stock price we have is $7.43 and we are not making any ACET forecasts at this time.
In addition, TradingView issued a Sell rating for ACET over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ACET. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ACET, please click here >>
The editors at financialmarketpress.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
FinancialMarketPress.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to FinancialMarketPress.com.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.